Jan 05, 2024 This Week in Cardiology Podcast

Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast, download the Medscape app or subscribe on Apple Podcasts, Spotify, or your preferred podcast provider. This podcast is intended for healthcare professionals only.

In This Week’s Podcast

For the week ending January 5, 2024, John Mandrola, MD, comments on the following news and features stories: Neuro-modulation in HF, private equity as hospital owners, HCM, SCD and ICD re-evaluated, and peer review.

Barostimulation for HF

• FDA Expands Label for CVRx Barostim System in HF

• BeAT HF trial

About a year ago, a vascular surgeon friend asked me what I thought of this carotid stimulation device. I’m like, a) why are you asking, and b) what are you talking about?

Apparently, our hospital system was considering doing barostimulation and it required a vascular surgeon. He told me he had looked at the study, and it’s not that impressive.

At the time I briefly looked at the BEAT HF study, and thought not much here, but, I paid it little attention. Mainly because this therapy didn’t have much traction.

Well, over the holidays, the FDA approved an expanded label for the Barostim neuromodulation system in patients with